ABBVIE INC. - ABBV STOCK NEWS

Allergan Aesthetics, part of AbbVie (NYSE: ABBV), announced the national launch of JUVÉDERM® VOLUX™ XC on January 18, 2023. This long-lasting hyaluronic acid filler addresses moderate to severe loss of jawline definition and is available for adults over 21. 40% of consumers are considering treatment for their jawline in the next year. Clinical trials showed high patient satisfaction, with results lasting up to 12 months. The JUVÉDERM Collection is the top dermal filler choice in the U.S., and providers prefer it over competitors. Allergan also offers the Allē loyalty program for rewards on treatments.

Allergan Aesthetics, part of AbbVie (NYSE: ABBV), launched the SkinMedica® Even & Correct Collection on January 17, 2023. This new line includes three products designed to enhance skin tone and reduce hyperpigmentation: Advanced Brightening Treatment, Dark Spot Cream, and Brightening Treatment Pads. The collection is clinically proven and applicable to all skin types. According to a study, results can be seen within a week, with up to 84% of participants reporting improvements. The products contain a patent-pending LTN Complex™ and are priced at $178, $88, and $60, respectively. They can be purchased online and through licensed professionals.

AbbVie has partnered with Anima Biotech to develop mRNA biology modulators targeting oncology and immunology. The collaboration utilizes Anima's mRNA Lightning technology, which combines AI-driven phenotypic screening and small molecule modulation. AbbVie will pay Anima an upfront amount of $42 million and may pay up to $540 million in additional fees and milestones. This partnership aims to address challenging 'undruggable' targets and may expand to three more targets, enhancing AbbVie’s therapeutic capabilities.

Immunome has entered a multi-year collaboration with AbbVie to discover up to 10 novel target-antibody pairs through Immunome’s Discovery Engine. This agreement includes a $30M upfront payment and potential further payments totaling up to $70M for platform access, along with development milestones of up to $120M per target. AbbVie aims to enhance its oncology pipeline with Immunome’s innovative technology, which leverages human memory B cells for effective cancer therapeutics.

AbbVie and Immunome have announced a collaboration to discover up to 10 novel antibody-target pairs for oncology. Immunome will receive an upfront payment of $30M and could earn up to $70M in additional platform access fees, plus milestones totaling $120M per target and tiered royalties on global sales. This partnership underscores AbbVie's commitment to innovative cancer therapies and leverages Immunome's unique Discovery Engine, aimed at unlocking new therapeutic candidates for solid tumors. Both companies aim to enhance treatment approaches for patients with life-threatening cancers.

AbbVie (NYSE: ABBV) will disclose its fourth-quarter 2022 financial results on February 9, 2023, prior to market opening. A live webcast of the earnings conference call is scheduled for 8 a.m. CT and can be accessed via AbbVie's Investor Relations website. An archived version will be available later on the same day. AbbVie aims to innovate in various therapeutic areas including immunology, oncology, neuroscience, eye care, virology, and gastroenterology.

AbbVie (NYSE: ABBV) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 5:00 p.m. CT. The presentation will be led by Richard A. Gonzalez, chairman and CEO. Investors can access a live audio webcast via AbbVie's Investor Relations website, with an archived version available later that day. AbbVie focuses on innovative medicine across critical areas including immunology, oncology, and more. For updates, visit abbvie.com.

AbbVie announced that the FDA has approved VRAYLAR (cariprazine) as an adjunctive treatment for major depressive disorder (MDD) in adults who experience a partial response to standard antidepressant therapy. This approval marks the fourth indication for VRAYLAR, which is the first dopamine and serotonin partial agonist approved for common forms of depression. The clinical trials showed statistically significant improvements in depression symptoms and established tolerability, enhancing treatment options for approximately 20% of U.S. adults who may suffer from MDD.

AbbVie has submitted a supplemental New Drug Application (sNDA) for linaclotide (LINZESS®) to the U.S. FDA, seeking approval for treating functional constipation in children and adolescents aged 6 to 17. This submission is based on positive results from a Phase 3 trial involving 330 patients, where linaclotide significantly increased spontaneous bowel movement frequency and improved stool consistency compared to placebo. Safety assessments show acceptable tolerability, with diarrhea being the most common adverse event, occurring in 4.3% of linaclotide-treated patients.